Incretin mimetics are ideal candidate therapies for T2D as they exert their actions specifically during hyperglycaemic conditions and have the additional capacity to regulate body weight ( Since 2005, six incretin therapy drugs have been approved by the FDA (United States) and the MHRA (United Kingdom) for T2D treatment: Exenatide, Lixisenatide, Liraglutide, Dulaglutide, Semaglutide and Tirzepatide, all of which are administered daily or once weekly via subcutaneous injection
If ongoing lab work matters to your decision, that's a specific, checkable inclusion - not an assumption on this article's part
doi:10.1007/s12035-022-02811-9
Repurposing GLP-1 receptor agonists and novel dual/triple GLP-1, GIP, and glucagon agonists represent promising therapeutic strategies that have shown to be effective in targeting inflammation, tau phosphorylation, synaptic dysfunction, insulin resistance, and oxidative stress
First, its important to understand how adequate GLP-1 secretion plays a role, in weight reduction according to BioMed Central, it delays the process of stomach emptying to make you feel full for periods after meals
